Vedolizumab (Entyvio), developed by Takeda Pharmaceuticals, is a leading gut-selective α4β7 integrin antagonist used for treating inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Approved in over 70 countries, the drug is also under re...Read More »
October 16, 2025
Denosumab, marketed by Amgen under the brand names Prolia and Xgeva, is a fully human monoclonal antibody that inhibits RANK ligand (RANKL) to suppress osteoclast formation and bone resorption. Prolia is prescribed for osteoporosis and bone loss associated with hormonal therapy, administered as a ...Read More »
October 15, 2025
Tocilizumab (Actemra), developed by Roche, is a leading interleukin-6 (IL-6) inhibitor used for treating autoimmune diseases like rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS). Approved in over 100 countries, the drug is also under regulatory rev...Read More »
October 15, 2025
Insulin Degludec (Tresiba), developed by Novo Nordisk, is a leading ultra-long-acting basal insulin used for managing type 1 and type 2 diabetes. Approved in over 80 countries, Tresiba offers a flexible dosing schedule, extended 42-hour action, and reduced risk of hypoglycemia, making it a preferr...Read More »
October 14, 2025
Darolutamide (Nubeqa) and Enzalutamide (Xtandi) are androgen receptor inhibitors in prostate cancer treatment. Darolutamide, developed by Bayer and Orion, is protected by U.S. patents with generic entry estimated in 2038. It is approved in over 80 markets globally and is under regulatory review fo...Read More »
October 14, 2025
Mobility disability refers to any condition that restricts or impairs a person's ability to move freely or carry out physical activities independently. Assistive devices like wheelchairs, walkers, prosthetic limbs, and white canes are vital tools that support individuals with mobility challenges c...Read More »
October 13, 2025
Remdesivir (Veklury) market remains stable but has transitioned from pandemic-driven demand to a more selective therapeutic use profile. Its utilization is largely concentrated in hospital settings for managing severe COVID-19 cases and select viral infections under investigation. While global dem...Read More »
October 13, 2025
Influenza A and B continue to impose a significant global health and economic burden each year, driving the need for fast, accurate, and accessible diagnostic solutions. The diagnostics landscape for influenza has undergone a profound transformation in recent years, evolving from conventional anti...Read More »
October 13, 2025
The U.S. medical claims market is one of the largest transactional ecosystems in the world, processing over 10 billion medical claims annually. The rising utilization of healthcare, fueled by an aging population and the increasing prevalence of chronic diseases, has led to an increase in the numbe...Read More »
October 13, 2025
Ibrutinib, marketed as Imbruvica by AbbVie and Janssen, has become a cornerstone treatment in oncology, particularly for hematologic malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The drug has delivered strong market performance due to its proven efficacy i...Read More »
October 13, 2025
The North American metal stamping for electronics market continues to expand steadily. In 2024, it was valued at approximately USD 15.56 billion and is projected to reach USD 24.56 billion by 2033, growing at a CAGR of 5.3%. Growth is driven by rising demand for precision metal components in consu...Read More »
October 10, 2025
Olaparib (Lynparza), developed by AstraZeneca and Merck, is a leading PARP inhibitor approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. With global revenues reaching approximately USD 3.67 billion in 2024, Lynparza has established itself as a top-performing oncology t...Read More »
October 9, 2025
Bevacizumab, marketed as Avastin by Genentech (a Roche subsidiary), has become a cornerstone treatment for oncology indications, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma. Its strong market performance has been driven by its anti-angiogenic efficacy and e...Read More »
October 8, 2025
Eculizumab, marketed as Soliris by Alexion Pharmaceuticals, is a critical treatment for rare and life-threatening conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Its unique mechanism of action, as a complement inhibitor, has positioned it...Read More »
October 8, 2025
Secukinumab (Cosentyx), developed by Novartis, is a leading IL-17A inhibitor approved for multiple immune-mediated conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, making it a cornerstone of...Read More »
October 7, 2025
Nivolumab, marketed as Opdivo by Genentech (a Roche subsidiary), has become a cornerstone treatment for oncology indications, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma. Its strong market performance has been driven by its anti-angiogenic efficacy and exte...Read More »
October 7, 2025
Non-hospital imaging (mobile radiography, mobile mammography, point-of-care ultrasound, mobile CT/MRI trailers, and teleradiology) is expanding rapidly, driven by aging populations and long-term care needs, rural and underserved population demand, workforce shortages and hospital capacity constrai...Read More »
October 6, 2025
Enhertu, marketed as Enhertu by Daiichi Sankyo and AstraZeneca, has become a key therapeutic for HER2-positive and HER2-low cancers, including advanced breast cancer, metastatic non-small cell lung cancer (NSCLC), and gastric cancer, with strong market performance driven by its targeted mechanism ...Read More »
October 3, 2025
Pembrolizumab (Keytruda), developed by Merck & Co., has transformed the oncology landscape as a PD?1 immune checkpoint inhibitor approved for multiple cancers, including NSCLC, melanoma, head and neck squamous cell carcinoma, and urothelial carcinoma. With global revenues exceeding USD 29 bill...Read More »
October 3, 2025
Ustekinumab, marketed as Stelara by Janssen Biotech, has become a cornerstone treatment for autoimmune conditions, including psoriasis, Crohn's disease, and psoriatic arthritis. Its strong market performance has been driven by its proven efficacy and broad therapeutic applications. As the expirati...Read More »
September 30, 2025